LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB ...

Topline data expected in 1Q 2028Phase 2bipolar depression trial initiation follows positive Phase 2 results in acute schizophreniaNEW YORK, Jan.

LB Pharmaceuticals initiates Phase 2 trial of LB-102

LB Pharmaceuticals (LBRX) announced the initiation of a Phase 2 trial evaluating the efficacy and safety of LB-102 in patients with bipolar depression. LB-102, a novel, once-daily, oral ...
Seeking Alpha

LB Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial of LB-102 in ...

NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of psychiatric diseases including ...
Business Wire

Segal Trials Leads Phase 2 Schizophrenia Trial of LB-102 Toward Primary Endpoint

MIAMI LAKES, Fla.--(BUSINESS WIRE)--Segal Trials, a privately held clinical research network specializing in acute schizophrenia and other psychiatric disorders, has released enrollment performance ...

LB Pharmaceuticals Inc: LB Pharmaceuticals Announces $100.0 Million Private Placement

LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia ...
abc27

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with ...

BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (“CervoMed” or the “Company”), a clinical-stage company focused on developing treatments for age-related neurologic disorders, ...